Skip to main content

Posts tagged with "The Dark Side"

  • Business and Markets

    Valeant: Bound to be a Good Explanation, Right?

    For those of you following this saga, here’s the latest from Bronte Capital, SIRF, and the Wall Street Journal on the wonderfulness that is Valeant Pharmaceuticals. Marvel at companies that aren’t supposed to be related that share phone numbers and web sites, at Valeant prescriptions being mailed all over the place, including plenty of… Read More
  • Business and Markets

    Looking Under the Valeant Pharmaceuticals Rock

    When I last discussed Valeant Pharmaceuticals, in this rather testy post, I expressed a desire for the company to get what’s coming to it. Little did I know. Valeant recently announced that they’re not planning on growing by what’s brought them along so far (the sorts of price-raising described in that post and the links… Read More
  • The Dark Side

    Scams, Attended By Frauds

    A puzzled reader sent along this notice of a meeting next month in London. It’s ostensibly on natural products, but he noted a conspicuous lack of anyone he’d ever actually heard of in the field, and the more he read into the details of the conference, the more otherworldly it seemed. He’s right. There have… Read More
  • Infectious Diseases

    The End Result of Faked Results

    Oh, man. Here’s another example of an old, sad story – just a little fakery at the beginning, and here’s what it leads to: Government prosecutors said (Dong-Pyou) Han’s misconduct dates to 2008 when he worked at Case Western Reserve University in Cleveland under professor Michael Cho, who was leading a team testing an experi… Read More
  • The Dark Side

    A Retraction, Ten Years Later

    Here’s an odd thing, noted by a reader of this site. Organic Letters has a retraction of a paper in the Baldwin group at Oxford, “Biomimetic Synthesis of Himbacine”. This Letter has been retracted, as it was found that (a) spectra of the linear precursor, compound 14, differed when its synthesis was repeated and (b) Read More
  • The Dark Side

    Some Sales Force

    If you want to see the real underbelly of pharmaceutical sales and promotion, here it is. Insys Therapeutics makes a sublingual spray formulation of fentanyl called Subsys, and has been doing very well with it. But that seems to be, to a good extent, the product of, well, let’s just call them extremely aggressive sales… Read More
  • Clinical Trials

    Giving Ambulance Chasing a Bad Name

    My Twitter feed alerted me to this press release, surely one of the sleaziest I’ve seen in a long time. It’s not that there’s no actual data in it, although that’s bad enough. Nor is it that it talks about “promising results”, even though the trial it touts is still underway, even though that’s pretty… Read More
  • The Dark Side

    People Only Fake Things That Are Valuable

    The fake peer review scandals just keep on coming. BioMed Central noticed problems with a few papers last fall, but they’ve now had to pull 43 papers from their journals: Some of the manipulations appear to have been conducted by third-party agencies offering language-editing and submission assistance to authors. It is unclear whether the aut… Read More
  • The Dark Side

    Three More Retractions

    Ouch. When the “unclick” work from the Bielawski lab at Texas was found not to hold up, the word was that other papers involving the now-hard-to-find co-author (Kelly Wiggins) were being looked over. And here come three more retractions. They all cite scientific misconduct on the part of “one of the co-authors” who was affil… Read More
  • The Dark Side

    Unclick Undone, Unsurprisingly

    The now-notorious “unclick” paper has been retracted. Last summer saw an editorial “Expression of Concern”, and later it was reported by C&E News that a common author (Kelly Wiggins) of all three papers in this area had confessed to fabricating data. In light of this, the retraction notice is interesting. It makes refer… Read More